X4 Pharmaceuticals (XFOR) Enterprise Value (2017 - 2025)
X4 Pharmaceuticals (XFOR) posted Enterprise Value of -$217.0 million for Q4 2025, down 211.71% on a QoQ basis from -$69.6 million in Q3 2025, and down 289.68% year-over-year from $114.4 million in Q4 2024.
X4 Pharmaceuticals (XFOR) Enterprise Value (2017 - 2025) Analysis & Trends
X4 Pharmaceuticals' Enterprise Value history runs 9 years deep, the most recent figure standing at -$217.0 million for Q4 2025.
- Quarterly Enterprise Value fell 289.68% year-over-year to -$217.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$217.0 million (down 289.68% YoY) and the FY2025 annual result came in at -$217.0 million, down 289.68% from the prior year.
- Enterprise Value was -$217.0 million for Q4 2025 at X4 Pharmaceuticals, down from -$69.6 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$39.2 million in Q2 2025 and bottomed at -$217.0 million in Q4 2025.
- A 5-year average of -$93.6 million and a median of -$87.6 million in 2021 frame the typical range for Enterprise Value.
- Peak annual rise in Enterprise Value reached 73.36% in 2025, while the deepest fall reached 289.68% in 2025.
- X4 Pharmaceuticals' Enterprise Value stood at -$81.8 million in 2021, then sank by 48.82% to -$121.7 million in 2022, then increased by 18.49% to -$99.2 million in 2023, then surged by 43.86% to -$55.7 million in 2024, then sank by 289.68% to -$217.0 million in 2025.
- Business Quant data shows XFOR's Enterprise Value at -$217.0 million in Q4 2025, -$69.6 million in Q3 2025, and -$39.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | -61.40 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.83 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -1.91 Bn |
| 10 | X4 Pharmaceuticals | 167.90 Mn | -49.15 Mn | 2.20 Mn | -217.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -217.05 Mn |
| Sep 30, 2025 | -69.63 Mn |
| Jun 30, 2025 | -39.22 Mn |
| Mar 31, 2025 | -40.26 Mn |
| Dec 31, 2024 | -55.70 Mn |
| Sep 30, 2024 | -97.41 Mn |
| Jun 30, 2024 | -147.22 Mn |
| Mar 31, 2024 | -60.49 Mn |
| Dec 31, 2023 | -99.22 Mn |
| Sep 30, 2023 | -131.58 Mn |
| Jun 30, 2023 | -136.43 Mn |
| Mar 31, 2023 | -93.40 Mn |
| Dec 31, 2022 | -121.72 Mn |
| Sep 30, 2022 | -79.86 Mn |
| Jun 30, 2022 | -47.38 Mn |
| Mar 31, 2022 | -66.40 Mn |
| Dec 31, 2021 | -81.79 Mn |
| Sep 30, 2021 | -76.40 Mn |
| Jun 30, 2021 | -95.20 Mn |
| Mar 31, 2021 | -114.90 Mn |